2012 ACR/ARHP Annual Meeting

November 9-14, 2012. Washington, DC.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 743

Anemia and the Onset of Gout in a Population-Based Cohort of Adults: Atherosclerosis Risk in Communities Study
Abstract Number: 766

Anemia May Provide Clinically Relevant Information Beyond Conventional Disease Activity Assessment to Predict Radiographic Damage Progression in Rheumatoid Arthritis
Abstract Number: 781

Ankylosing Spondylitis Is Associated with an Increased Risk of Osteoporotic Fractures: A Population-Based Cohort Study
Abstract Number: 1612

Ankylosing Spondylitis Is Associated with Single Nucleotide Polymorphisms in Loci Implicating Four Aminopeptidases
Abstract Number: 2213

Ankylosing Spondylitis Is Strongly Related to Clinical Spine Fractures Independently of Drugs Use: A Register-Based Case-Control Study
Abstract Number: 2088

Annexin A1 Receptor Agonist Suppresses Development of Inflammatory Arthritis
Abstract Number: 1732

Annexin A5 Resistance Identifies a Subset of Thrombosis Patients in Systemic Lupus Erythematosus
Abstract Number: 544

Anterior Chest Wall Pain in Recent Inflammatory Back Pain. Data From the DESIR Cohort
Abstract Number: 1771

Anti Carbamylated Protein Antibodies (Anti-CarP) Are Present in Arthralgia Patients and Predict the Development of Rheumatoid Arthritis
Abstract Number: 31

Anti Citrullinated Protein Antibodies From Synovial Fluid of Rheumatoid Arthritis Patients Enhance Osteoclastogenesis
Abstract Number: 2581

Anti- Citrullinated Protein Antibodies but Not Rheumatoid Factor Are Associated with Larger Bone Erosions in rheumatoid arthritis patients- a Cross-Sectional Micro Computed Tomography Study
Abstract Number: 1402

Anti-ApoA1 Antibodies Associate with Disease Activity in Lupus and Are Lower in Patients Taking Hydroxychloroquine: A Longitudinal Analysis of 398 Samples
Abstract Number: 1605

Anti-Citrullinated Peptide Autoantibodies to Rheumatoid Synovium Epitopes in Women and Risk of Future Rheumatoid Arthritis
Abstract Number: 27

Anti-Citrullinated Protein Antibodies As an Indicator of Bone Damage in the Citrullinated Collagen Induced Arthritis Model
Abstract Number: 1201

Anti-Citrullinated Protein Antibody Specific Fc Glycosylation Patterns in Arthralgia Patients

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].